NanoSight

Press Release

NanoSight Recognised by Deloitte as the UK's Fastest Growing Biotech Company in their 2011 Technology Fast 50 Rankings

Salisbury, UK, 9th November 2011: NanoSight, leading manufacturers of unique nanoparticle characterization technology, are in the Deloitte 2011 Fast 50 list of the fastest growing technology companies in the UK. In the world of biotech, NanoSight has made it to number one nationwide and overall is the fastest growing of all technology companies in the South West and Wales region of the UK.

NanoSight has been ranked in the Deloitte 2011 UK Technology Fast 50, which recognises the 50 fastest-growing technology companies in the UK. The company has also been named as a winner in the Technology Fast 500 EMEA 2011 rankings, which recognises the 500 fastest-growing technology companies across Europe, the Middle East and Africa. Both programmes are based on percentage revenue growth over the last five years.

NanoSight has grown by more than 800 per cent over the past five years and entered the league table for the first time at 38th in the list. The company is the only South West firm in the annual ranking and the highest-ranking biotech firm nationally.

NanoSight was founded in 2004 by Dr Bob Carr and John Knowles after Carr discovered a technology which allows particles so small they could not be detected by the best optical microscopes to be seen, sized and counted, in just minutes, for a fraction of the cost of electron microscopes. The business was initially supported by funding from Winchester-based venture capitalists Shackleton Ventures and the Bristol office of Yorkshire Fund Manager Equity Partners, supplemented by angel finance accessed through the South West Angel and Investors Network (SWAIN) and London-based Lesmoir-Gordon, Boyle & Co.

Since 2005, NanoSight has grown sales by around 70 per cent annually, year on year, and now employs 23 people in the UK. The firm sells its products all over the world, with around 90 per cent of its sales outside the UK. The most significant growth is in pharmaceuticals and life sciences, where budgets have remained largely unaffected by the global financial condition. There are now more than 400 NanoSight instruments in use worldwide and this number continues to grow as the firm's products are cited almost daily in fresh academic papers.

Jeremy Warren, CEO of NanoSight, commented: "What we sell is unique, and we estimate we are currently only in single digits in terms of percentage of market penetration. So what limits our growth most isn't the market, but having the technical and sales staff to go and sell! The South West has been the ideal place for us to base our business as our universities offer the high-calibre science graduates we're looking for to help us continue to develop the business."

To find out about the company and to learn more about particle characterization using NanoSight's unique nanoparticle tracking analysis solutions, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company's electronic newsletter.

NanoSight CEO, Jeremy Warren (left) and NanoSight Founder & CTO, Bob Carr (right)

About NanoSight

NanoSight delivers the world’s most versatile and proven multi-parameter nanoparticle analysis in a single instrument.

NanoSight’s “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Particle size, concentration, Zeta potential and aggregation can all be analyzed while a fluorescence mode provides differentiation of labelled particles. This particle-by-particle methodology goes beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions.

NanoSight’s comprehensive characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, in nanotoxicology and in biodiagnostics. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner.
NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles. As functionalized nanoparticles increasingly fulfill their potential in biodiagnostics, NanoSight is ever more the analytical platform of choice.

NanoSight demonstrates worldwide success through rapid adoption of NTA, having installed more than 300 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. In addition to this user base more than 250 third party papers citing NanoSight results consolidate NanoSight’s leadership position in nanoparticle characterization.
For more information, visit www.nanosight.com.

About Deloitte

Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu Limited (“DTTL”), a UK private company limited by guarantee, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTTL and its member firms.

For further information
Please contact NanoSight direct or their marketing agency, Talking Science Limited: